2nd generation CD40L blocker safely reduces new brain lesions in Phase 2 trial | Frexalimab may help reduce MS activity with fewer side effects: Trial data

Frexalimab, a second-generation CD40L blocker, safely reduced the number of new active brain lesions in relapsing MS patients in a Phase 2 trial.

Related Keywords

Colorado ,United States ,Erik Wallstr ,Gavin Giovannoni ,Consortium Of Multiple Sclerosis Center ,London School Of Medicine ,Queen Mary University Of London ,Relapsing Multiple Sclerosis ,Randomized Controlled Phase ,Multiple Sclerosis Center ,London School ,Queen Mary University ,